PULSE Partner Perspectives

For over 150 years, Michigan has been at the forefront of bringing biopharmaceutical advances to patients across the country and around the world. This is not simply a byproduct of economic luck or chance, but rather the culmination of competitive mergers and...

In a recent blog post, PULSE partner Colorado Bioscience Association (CBSA) highlighted the fundamental role of pro-innovation mergers and acquisitions in driving life sciences innovation and economic growth in Colorado and beyond.   Read their blog post below: ...

Leading organizations are expressing concern about the impact of the Federal Trade Commission (FTC)’s final Hart-Scott-Rodino (HSR) premerger notification rule, including the chilling effect it could have on biopharmaceutical and life sciences innovation.   While the...

New Jersey has long been home to some of the world’s leading research-based biopharmaceutical companies. Many have made New Jersey a base for their global, North American, or U.S. operations. Aside from their contributions to human health and patients worldwide, our state’s biopharmaceutical community is responsible for 16% of New Jersey’s Gross Domestic Product, contributing $120.9 billion in total impact to our state economy annually.

PULSE had a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. Joan, who has led AZBio since 2011, has a vested interest in making Arizona a place where...